Yesterday, Aug. 24, 2015, 130 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $548.22 to $210,501,361.00.

Highlighted Stocks Traded by Insiders:

Vascular Solutions (VASC) - FREE Research Report

Saucedo Jorge, who is Director at Vascular Solutions, sold 2,285 shares at $38.00 on Aug. 24, 2015. Following this transaction, the Director owned 27,035 shares meaning that the stake was reduced by 7.79% with the 2,285-share transaction.

The shares most recently traded at $36.09, down $1.91, or 5.29% since the insider transaction. Historical insider transactions for Vascular Solutions go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 32,130
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 73,922

The average volume for Vascular Solutions has been 127,400 shares per day over the past 30 days. Vascular Solutions has a market cap of $652.7 million and is part of the health care sector and health services industry. Shares are up 31.66% year-to-date as of the close of trading on Monday.

Vascular Solutions, Inc., a medical device company, provides various solutions to interventional cardiologists, interventional radiologists, electro physiologists, and vein practices worldwide. The company has a P/E ratio of 53.1. Currently, there are 3 analysts who rate Vascular Solutions a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VASC - FREE

TheStreet Quant Ratings

rates Vascular Solutions as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Vascular Solutions Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Kindred Healthcare (KND) - FREE Research Report

Rousseau Jon B, who is EVP, President, KRS at Kindred Healthcare, sold 7,700 shares at $21.36 on Aug. 24, 2015. Following this transaction, the EVP, President, KRS owned 41,333 shares meaning that the stake was reduced by 15.7% with the 7,700-share transaction.

The shares most recently traded at $20.32, down $1.04, or 5.11% since the insider transaction. Historical insider transactions for Kindred Healthcare go as follows:

  • 4-Week # shares sold: 7,835
  • 12-Week # shares sold: 13,235
  • 24-Week # shares bought: 8,000
  • 24-Week # shares sold: 33,845

TheStreet Recommends

The average volume for Kindred Healthcare has been 792,200 shares per day over the past 30 days. Kindred Healthcare has a market cap of $1.8 billion and is part of the health care sector and health services industry. Shares are up 10.95% year-to-date as of the close of trading on Monday.

Kindred Healthcare, Inc. provides healthcare services in the United States. It operates in four divisions: Hospital, Nursing Center, Rehabilitation, and Care Management. The stock currently has a dividend yield of 2.28%. Currently, there are 3 analysts who rate Kindred Healthcare a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KND - FREE

TheStreet Quant Ratings

rates Kindred Healthcare as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, poor profit margins and generally higher debt management risk. Get the full

Kindred Healthcare Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Carlyle Group L P (CG) - FREE Research Report

Youngkin Glenn A., who is Officer at Carlyle Group L P, bought 100,000 shares at $21.21 on Aug. 24, 2015. Following this transaction, the Officer owned 431,910 shares meaning that the stake was boosted by 30.13% with the 100,000-share transaction.

The shares most recently traded at $21.31, up $0.10, or 0.47% since the insider transaction. Historical insider transactions for Carlyle Group L P go as follows:

  • 4-Week # shares sold: 8,443
  • 12-Week # shares sold: 8,443
  • 24-Week # shares bought: 150,000
  • 24-Week # shares sold: 17,962

The average volume for Carlyle Group L P has been 802,700 shares per day over the past 30 days. Carlyle Group L P has a market cap of $1.7 billion and is part of the financial sector and financial services industry. Shares are down 27.35% year-to-date as of the close of trading on Monday.

The Carlyle Group LP is an investment firm specializing in direct and fund of fund investments. The stock currently has a dividend yield of 14.13%. The company has a P/E ratio of 14.9. Currently, there are 6 analysts who rate Carlyle Group L P a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CG - FREE

TheStreet Quant Ratings

rates Carlyle Group L P as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full

Carlyle Group L P Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.